{"nctId":"NCT01072344","briefTitle":"Long Term Chamomile Therapy for Anxiety","startDateStruct":{"date":"2010-02"},"conditions":["Generalized Anxiety Disorder"],"count":180,"armGroups":[{"label":"Chamomile Extract","type":"EXPERIMENTAL","interventionNames":["Drug: Chamomile (Matricaria recutita)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Chamomile (Matricaria recutita)"]}],"interventions":[{"name":"Chamomile (Matricaria recutita)","otherNames":["Chamomile"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women at least 18 years old (all races and ethnicity)\n* DSM IV diagnosis of GAD as the primary anxiety disorder\n* Baseline GAD-7 score ≥ 10\n* Baseline CGI/S score at least 4\n* Not taking anti-anxiety medication (e.g., Benzodiazepines, buspirone, antidepressants)\n* Not taking antidepressant, mood stabilizer, or tranquilizer therapy for a prior DSM IV Axis I mood disorder that is in remission\n* Able to understand and provide informed consent\n* Able to participate in a 38-week study\n\nExclusion Criteria:\n\n* Patients \\< 18 years old\n* Primary DSM IV Axis I anxiety disorder other than GAD (e.g., panic disorder with or without agoraphobia, phobia disorder, acute stress disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance-induced anxiety disorder)\n* Current DSM IV Axis I psychotic disorder\n* Substance abuse or dependence within the prior 3 months\n* Current DSM IV Axis I bipolar or major depressive disorder \\[Note: Patients with co-morbid depressive disorder NOS (e.g., minor depression, recurrent brief depressive disorder, or premenstrual dysphoric disorder (PMDD)\\] will not be excluded\n* Unstable medical condition\n* Allergy to chamomile\n* Documented allergy to plants of the asteraceae family (e.g., ragweed, asters, chrysanthemum)\n* Allergic to mugwort or birch pollen\n* Concurrent anti-anxiety tranquilizer, antidepressant or mood stabilizer therapy\n* Concurrent use of over-the-counter anti-anxiety and/or antidepressant preparations (e.g., chamomile, St. John's Wort, kava kava)\n* Concurrent use of established antidepressant, mood stabilizer, or tranquilizer therapy for pre-existing affective disorder. \\[Note: Patients with a history of affective disorder (in remission) who are not currently taking antidepressant, mood stabilizer, or tranquilizer therapy are not excluded from the trial\\]\n* Women of child-bearing potential not willing to use a medically proven form of contraception\n* Positive pregnancy test\n* Actively suicidal or suicide attempt within the preceding 12 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Relapse in Each Treatment Condition.","description":"The primary outcome was time to relapse during continuation therapy, analyzed using Cox proportional hazards. Relapse is dichotomously defined as an increase in CGI/S (a clinician-rated global measure of anxiety's severity) score from ≤ 3 (at study visit 6) to ≥ 4 (on two consecutive scheduled or unscheduled study visits ≥ 2 weeks apart) plus meeting DSM IV-TR criteria for GAD (minus the 6-month time criterion).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":"8.4"},{"groupId":"OG001","value":"6.3","spread":"3.9"}]}]}]},{"type":"SECONDARY","title":"The Proportion of Subjects in Each Treatment Condition Who Relapse.","description":"The proportion of subjects in each treatment condition who relapsed after randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency, Severity, and Duration of Treatment-emergent Adverse Events.","description":"We will report the frequency, severity, and duration of treatment-emergent adverse events by treatment arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Discontinuation Symptoms at the Start of Double-blind Therapy in Each Treatment Condition.","description":"Discontinuation emergent signs and symptoms checklist (DESS) is a patient-rated measure of the presence and severity of discontinuation symptoms occurring after medication discontinuation. %","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Early Study Discontinuation in Each Treatment Condition.","description":"This is the # of subjects who discontinued the study during randomization phase due to other reasons.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":["taste perversion","Nausea","Bruising","Congestion","Decreased platelet count"]}}}